US Merger & Acquisition SEC Filings — March 17, 2026

17-03-2026

Eureka Acquisition Corp issued an interest-free promissory note for $150,000 to Marine Thinking Inc. on March 13, 2026, as disclosed in an 8-K filing on March 17, 2026. The note matures upon consummation of a Business Combination or the Company's term expiry and may be converted by the Payee into private units at $10 per unit. No period-over-period financial metrics are provided in the filing.

• ·Note governed by New York law
• ·Conversion notice required at least two business days prior to Business Combination closing
• ·No personal liability for officers, directors, employees, or stockholders
• ·Prospectus File No. 333-277780 referenced

17-03-2026

Pelican Acquisition Corp disclosed via 8-K recent interviews and discussions on March 13-16, 2026, featuring Greenland Energy Company CEO Robert Price and incoming director Larry G. Swets, Jr., promoting the pending Business Combination (deSPAC merger with Greenland Exploration Limited, March GL, and PubCo). Transcripts are furnished as Exhibits 99.1 and 99.2, with references to the S-4 registration statement effective February 17, 2026. The filing emphasizes forward-looking statements and extensive risks, including potential delays, redemptions, regulatory issues, and failure to complete the merger, without providing any financial metrics.

• ·Registration Statement on Form S-4 declared effective February 17, 2026.
• ·Pelican 10-Q filings: fiscal quarters ended July 31, 2025 (filed September 15, 2025), April 30, 2025 (filed June 27, 2025).
• ·Initial S-1 effective May 22, 2025.

17-03-2026

Nexentis Technologies Inc. (formerly N2OFF, Inc.) completed the closing of a Securities Exchange Agreement on March 15, 2026, transferring approximately 98% of its ownership in Save Foods Ltd. to Voice Assist, Inc. in exchange for 19.99% of Voice Assist's common stock on a fully-diluted basis. The company also maintains a Services Agreement with Voice Assist for advisory services, entitling it to deferred cash up to a $1M cap, royalties on new projects, and a share of Ecolab Gross Proceeds through at least 2026.

• ·Agreement originally dated January 13, 2026, with prior disclosure in 8-K filed that date.
• ·Services Agreement term through calendar year 2026 with extension rights until consideration fully received.
• ·Exhibits include Securities Exchange Agreement (10.1) and Services Agreement (10.2), incorporated by reference from January 13, 2026 8-K.

17-03-2026

Drugs Made In America Acquisition II Corp. (DMIIU), a SPAC listed on NASDAQ, entered into a non-binding Letter of Intent (LOI) effective March 5, 2026, with Alpha Multi Family Office (Investor) and S.E.E. Capital Partners Ltd. (Transaction Advisor) for a proposed $1.5M Senior Convertible Note to provide bridge financing for operational expenses and pursuit of a business combination. The funds will be held in escrow and convertible into discounted preferred equity upon events like execution or closing of a business combination agreement. No definitive agreements have been executed yet, and the LOI includes exclusivity for negotiations.

• ·LOI governed by laws of the State of Israel with exclusive jurisdiction in Tel Aviv courts.
• ·Conversion triggers include execution of definitive business combination agreement, closing of business combination, or restructuring of sponsor/capital structure.
• ·In case of no business combination, note subject to repayment or alternative consideration per definitive agreements.
• ·SEC 8-K filed March 17, 2026, covering Items 1.01, 2.03, 8.01, 9.01.

17-03-2026

Fulgent Genetics, Inc. (NASDAQ: FLGT) completed the acquisition of certain assets of Bako Diagnostics and StrataDx for a total combined purchase price of approximately $56.9 million in cash, subject to post-closing adjustments, as previously announced on December 22, 2025. The deal expands Fulgent's laboratory services into specialty pathology and dermatopathology. While no immediate financial impacts are quantified, forward-looking statements note potential integration risks and challenges in realizing benefits.

• ·Acquisition previously announced on December 22, 2025.
• ·Piper Sandler & Co. acted as exclusive financial advisor and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as legal counsel to Fulgent.
• ·EV Health Partners acted as exclusive financial advisor and Latham & Watkins LLP as legal counsel to Consonance Capital Partners, Bako Diagnostics, and StrataDx.
• ·Fulgent's Form 10-K for fiscal year ended December 31, 2025, filed February 27, 2026.

17-03-2026

Alexander & Baldwin, Inc. (ALEX) has been taken private through the completion of an acquisition by a joint venture formed by MW Group, Blackstone Real Estate, and DivcoWest, valued at approximately $2.3 billion enterprise value including debt. Shareholders received $21.20 per share in cash, net of a $0.35 Q4 2025 dividend (resulting in $20.85 net), following approval at a special meeting on March 9, 2026. A&B's common stock has ceased trading on the NYSE and the company is now privately held.

• ·Transaction initially announced on December 8, 2025
• ·Shareholder approval at Special Meeting on March 9, 2026
• ·Q4 2025 dividend record date December 19, 2025; paid January 8, 2026
• ·A&B's 156-year history in Hawaiʻi real estate sectors including agricultural, transportation, tourism, construction, residential, and commercial

17-03-2026

Israel Acquisitions Corp entered into a third amendment to its Business Combination Agreement (BCA) with Gadfin Ltd. and Gadfin Regev Holdings Ltd. on March 13, 2026, extending the termination date under Section 7.1(d) to April 15, 2026, while all other termination rights remain unchanged. This follows prior amendments dated January 26, 2025 (original BCA), July 2, 2025, and December 31, 2025. No financial terms were revised in this amendment.

• ·Securities trade on OTC Markets: Units (ISLUF), Class A ordinary shares (ISRLF), Redeemable warrants (ISLWF)
• ·Previous BCA filings: January 27, 2025 (original), July 3, 2025 (first amendment), March 9, 2026 (second amendment 8-K/A)

17-03-2026

Mountain Lake Acquisition Corp., a SPAC, entered into the Second Amendment to its Business Combination Agreement originally dated October 1, 2025, with Avalanche Treasury Corporation (Pubco), Avalanche Treasury Company LLC, and related parties including Astral Horizon, L.P., postponing the issuance of 2,000,000 Pubco Class A shares (Astral Post-Closing Shares) to Astral by 30 calendar days to occur on the 30th day following the Closing Date rather than the Company Merger Effective Date. The total Additional Merger Consideration Shares to Astral remain 4,000,000, with the other 2,000,000 as earnout shares in escrow. This procedural change occurs amid ongoing Proposed Transactions, including a planned private placement, with no financial impacts disclosed.

• ·Original Business Combination Agreement dated October 1, 2025; First Amendment effective October 1, 2025 and filed January 13, 2026
• ·Second Amendment dated and effective as of March 17, 2026 but retroactive to October 1, 2025
• ·Pubco Class A ordinary shares have par value of $0.0001 per share
• ·SPAC securities: MLACU (Units), MLAC (Class A ordinary shares), MLACR (Rights) listed on Nasdaq

17-03-2026

Vesicor Therapeutics, Inc., an early-stage biotech and proposed de-SPAC acquisition target for Black Hawk Acquisition Corp (Nasdaq: BKHA, BKHAU, BKHAR), appointed Michael Tolentino, M.D., as CEO effective March 17, 2026, succeeding founder Luo Feng, Ph.D., who transitions to Chief Scientific Officer. Tolentino brings over 20 years of biotech experience, including inventing contributions to Avastin, founding Acuity Pharmaceuticals (merged into OPKO Health), scientific founding Promedior (sold to Roche), and co-founding Aviceda Therapeutics (raised $207.5M Series C) and Avdarna Therapeutics. The company plans to accelerate IND-enabling studies toward a 2027 FDA IND submission, though it notes standard forward-looking risks including lack of current FDA approval and funding needs.

• ·Vesicor has not commenced FDA regulatory approval process for its sole product candidate as of March 17, 2026
• ·Tolentino co-founded Aviceda Therapeutics and served as CSO (2018-2021), CTO/CIO (2018-2025), and board member (2018-2024)
• ·Aikium's Yotta-ML platform targets GLP-1, GIP-1, glucagon agonists, checkpoint inhibitors, and cancer antigens for microvesicle conjugation

17-03-2026

IBM (NYSE: IBM) completed its acquisition of Confluent, Inc. (CFLT) on March 17, 2026, acquiring all outstanding common shares for $31 per share in cash, representing an enterprise value of approximately $11 billion. The deal integrates Confluent's data streaming platform, built on Apache Kafka and serving over 6,500 enterprises including 40% of the Fortune 500, with IBM's products like watsonx.data, IBM Z, IBM MQ, and webMethods Hybrid Integration to enable real-time data for enterprise AI. No financial performance declines or flat metrics are reported in the announcement.

• ·IDC estimates more than one billion new logical applications by 2028.
• ·BMW Group streams IoT data from 30+ production sites.

17-03-2026

Ondas Inc. (Nasdaq: ONDS) acquired INDO Earth Moving Ltd., a specialist in heavy engineering equipment for military programs, which was awarded a $140M tender as prime contractor for supplying dozens of Heavy Engineering Platforms, long-term maintenance, and sustainment infrastructure from a major military customer. Revenue generation from the tender is expected to begin in Q2 2026 over a two-year delivery period, with sustainment for at least four years, positioning Ondas to integrate INDO's expertise with its robotics from Roboteam, Apeiro Motion, and 4M Defense for future autonomous upgrades. The deal expands Ondas' autonomous systems portfolio into robotic heavy engineering platforms for defense and infrastructure applications.

• ·Program delivery of dozens of vehicles over two-year period with sustainment infrastructure for at least four years.
• ·Earnings conference call scheduled for March 25, 2026 at 8:30 a.m. Eastern Time with INDO outlook.

17-03-2026

WinVest Acquisition Corp., a SPAC, entered into an interest-free promissory note with WinVest SPAC LLC for a principal amount of up to $180,000, to be drawn in up to six $30,000 increments and funded directly into its trust account for the benefit of unredeemed common stockholders. The note matures upon consummation of a business combination or the company's liquidation, with repayment limited to funds outside the trust account if no business combination occurs. No performance declines or flat metrics are present, as this is a new financing arrangement providing working capital support.

• ·Note dated March 16, 2026; SEC filing date March 17, 2026
• ·Payee waives all claims against the trust account
• ·Governed by New York law; no assignment without Payee consent

17-03-2026

GalaxyEdge Acquisition Corp, a Cayman Islands SPAC, closed its IPO of 10,000,000 units at $10.00 per unit on March 5, 2026, generating $100M in gross proceeds. On March 12, 2026, underwriters fully exercised the over-allotment option, purchasing 1,500,000 additional units for $15M, while the company issued 7,500 private placement units to Equinox Capital Solutions Limited for $75K. No declines or flat performance reported in this update.

• ·Over-allotment option notified by underwriters on March 10, 2026.
• ·Press release dated March 10, 2026 furnished as Exhibit 99.1.
• ·Unaudited pro forma balance sheet as of March 12, 2026 attached as Exhibit 99.2.
• ·Audited balance sheet as of March 5, 2026 previously filed on March 10, 2026.